
TSXV company with zeo analyst coverage. 17 years of profitability. Q1 captures one month of a transformative acquisition, and they have a First-in-Canada product released yesterday. And yet nobodies noticing
BioSyent (TSXV: RX). Specialty pharma distributor. Profitable since 2009. Growing dividend raised every year since 2022.
On March 1, they acquired Oral Science, a profitable dental hygiene distributor, at 6.33x EBITDA. Q1 results include one month only. Pro-forma the combined entity: C$70M+ revenue, C$15.75M+ EBITDA, ~10x EV/EBITDA, net cash, zero long-term debt by Q3.
The day before I published this Health Canada approved Thyconvi, the first and only liquid levothyroxine in Canada. One of the most prescribed drug categories in the country. Every existing formulation is a tablet.
Check out more here
Not investment advice.